{
  "@context": "aku-v2",
  "@type": "concept",
  "@id": "medicine:vascular:procedures:angioplasty:pta-001",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-05T04:07:00.000Z",
    "contributors": ["copilot"],
    "confidence": 0.95,
    "status": "validated",
    "board_yield": "HIGH"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/procedures/angioplasty",
    "type": "procedure",
    "difficulty": "intermediate",
    "importance": "foundational"
  },
  "content": {
    "title": "Percutaneous Transluminal Angioplasty (PTA)",
    "definition": "Minimally invasive endovascular procedure using a balloon catheter to dilate a stenotic or occluded artery, restoring blood flow. First performed by Charles Dotter in 1964 and refined by Andreas Grüntzig. Foundation of modern endovascular intervention.",
    "key_concepts": [
      {
        "term": "Mechanism",
        "description": "Balloon inflation causes controlled plaque fracture, intimal/medial disruption, and vessel stretch → larger lumen. Plaque is redistributed, not removed"
      },
      {
        "term": "Basic Technique",
        "description": "Arterial access → wire crossing of lesion → balloon catheter positioning → inflation to rated burst pressure (8-12 atm typically) → deflation and withdrawal → angiographic assessment"
      },
      {
        "term": "Balloon Types",
        "description": "Standard (non-compliant for controlled sizing), compliant (conforms to vessel), high-pressure (for resistant lesions), cutting (blades for fibrotic lesions), scoring (for calcified lesions)"
      },
      {
        "term": "Drug-Coated Balloon (DCB)",
        "description": "Balloon surface coated with antiproliferative drug (usually paclitaxel); delivers drug to vessel wall during inflation; reduces restenosis compared to plain balloon; standard for femoropopliteal disease"
      },
      {
        "term": "Sizing",
        "description": "Balloon sized to reference vessel diameter (1:1 ratio); oversizing increases dissection/rupture risk; undersizing may be subtherapeutic. Measure with quantitative angiography or IVUS"
      },
      {
        "term": "Indications",
        "description": "Focal stenosis/occlusions of peripheral arteries; claudication or CLTI; aortoiliac, femoropopliteal, and tibial disease; renal artery stenosis; dialysis access"
      },
      {
        "term": "Immediate Complications",
        "description": "Dissection (flow-limiting vs non-flow-limiting); elastic recoil; residual stenosis; thrombosis; embolization; perforation/rupture; access site complications"
      },
      {
        "term": "Restenosis",
        "description": "Neointimal hyperplasia causing recurrent stenosis (typically 6-12 months); more common in long lesions, small vessels, diabetics; DCB reduces this"
      },
      {
        "term": "When to Stent",
        "description": "Flow-limiting dissection, elastic recoil >30% residual stenosis, or suboptimal result after PTA; also primary stenting for aortoiliac disease and renal artery stenosis"
      },
      {
        "term": "Post-Procedure Care",
        "description": "Antiplatelet therapy (aspirin ± clopidogrel); surveillance imaging at 3-6 months; risk factor modification; foot care in diabetics"
      }
    ],
    "clinical_features": {
      "snomed_codes": ["397193006"],
      "cpt_codes": ["37224", "37226", "37228", "37230", "37232", "37234"],
      "icd_10_codes": ["I70.2", "I70.3"]
    },
    "relationships": {
      "skos:broader": ["medicine:vascular:procedures:endovascular"],
      "skos:related": [
        "medicine:vascular:procedures:stenting",
        "medicine:vascular:procedures:atherectomy:ath-001",
        "medicine:vascular:pathology:pad:pad-009"
      ],
      "skos:narrower": []
    }
  },
  "pedagogical": {
    "learning_objectives": [
      "Understand the mechanism of balloon angioplasty",
      "Know appropriate balloon sizing principles",
      "Recognize indications for bailout stenting",
      "Understand the role of drug-coated balloons in reducing restenosis"
    ],
    "clinical_pearls": [
      "PTA mechanism = controlled injury (crack, stretch) NOT plaque removal",
      "Size balloon 1:1 to reference vessel diameter",
      "DCB is now standard for femoropopliteal disease (reduces restenosis)",
      "Stent for flow-limiting dissection or >30% residual stenosis",
      "Restenosis = neointimal hyperplasia, different from progression of atherosclerosis",
      "Dotter (1964) → Grüntzig (1970s) = history of PTA"
    ],
    "common_mistakes": [
      "Oversizing balloon (dissection, rupture)",
      "Using plain balloon when DCB available for femorpopliteal",
      "Not recognizing flow-limiting dissection (needs stent)",
      "Expecting single PTA to be curative (surveillance important)"
    ]
  }
}
